Income Taxes	9 Months Ended
Mar. 25, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company's effective tax rate was approximately 41.1% and 27.1% for the three months ended March 25, 2016 and March 27, 2015 respectively. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the three months ended March 25, 2016 were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit and U.S. Domestic Production Activities deduction. The discrete impact of research and development credits and U.S. Domestic Production Activities deduction is the result of a change in estimate resulting from the finalization of a new research and development credit study and U.S. Domestic Production Activities deduction study during the three months ended March 25, 2016; the tax benefit for the change in estimate was reflected in its entirety in the three months ended March 25, 2016. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the three months ended March 27, 2015 were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit. The discrete impact of research and development credits is the result of a change in estimate resulting from the finalization of a new research and development credit study during the three months ended March 27, 2015. A tax benefit for the change in estimate was reflected in its entirety in the three months ended March 27, 2015. The Company's effective tax rate was 42.6% and 36.4% for the nine months ended March 25, 2016 and March 27, 2015, respectively. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the nine months ended March 25, 2016 and March 27, 2015, respectively, were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit and U.S. Domestic Production Activities deduction in the current year, as well as the discrete tax benefits related to research and development tax credits in the prior year period. As of March 25, 2016, the recorded liability for uncertain tax positions under the measurement criteria of Accounting Standards Codification ("ASC") Topic 740, Income Taxes, was $2,067. The Company does not expect the amount of unrecognized tax benefits to materially change within the next twelve months. As of March 25, 2016, the Company had a tax benefit of $4,111 related to excess tax benefits from stock compensation. Pursuant to ASC Topic 718, a benefit of $1,473 was recorded to increase APIC as it reduced income taxes payable during the nine months ended March 25, 2016. In addition, a tax deficiency of $147 related to the expiration of vested stock options was recorded during the period to decrease APIC as it reduced deferred tax assets.

Income Taxes

The Company's effective tax rate was approximately 41.1% and 27.1% for the three months ended March 25, 2016 and March 27, 2015 respectively. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the three months ended March 25, 2016 were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit and U.S. Domestic Production Activities deduction. The discrete impact of research and development credits and U.S. Domestic Production Activities deduction is the result of a change in estimate resulting from the finalization of a new research and development credit study and U.S. Domestic Production Activities deduction study during the three months ended March 25, 2016; the tax benefit for the change in estimate was reflected in its entirety in the three months ended March 25, 2016. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the three months ended March 27, 2015 were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit. The discrete impact of research and development credits is the result of a change in estimate resulting from the finalization of a new research and development credit study during the three months ended March 27, 2015. A tax benefit for the change in estimate was reflected in its entirety in the three months ended March 27, 2015.

The Company's effective tax rate was 42.6% and 36.4% for the nine months ended March 25, 2016 and March 27, 2015, respectively. The primary reconciling items between the federal statutory rate of 35.0% and the Company's overall effective tax rate for the nine months ended March 25, 2016 and March 27, 2015, respectively, were the effect of state income taxes offset by discrete tax benefits related to the U.S. Research and Development credit and U.S. Domestic Production Activities deduction in the current year, as well as the discrete tax benefits related to research and development tax credits in the prior year period.

As of March 25, 2016, the recorded liability for uncertain tax positions under the measurement criteria of Accounting Standards Codification ("ASC") Topic 740, Income Taxes, was $2,067. The Company does not expect the amount of unrecognized tax benefits to materially change within the next twelve months.

As of March 25, 2016, the Company had a tax benefit of $4,111 related to excess tax benefits from stock compensation. Pursuant to ASC Topic 718, a benefit of $1,473 was recorded to increase APIC as it reduced income taxes payable during the nine months ended March 25, 2016. In addition, a tax deficiency of $147 related to the expiration of vested stock options was recorded during the period to decrease APIC as it reduced deferred tax assets.